| abstract |
The present invention provides 2-morpholin-4-yl-9H-purine and 5-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially Those substituted with 6-heteroaryl groups, which are unexpectedly PI3 kinase subtype-selective inhibitors with favorable pharmaceutical properties and are useful in the treatment of disorders associated with aberrant PI3K activity, such as cancer, immune dysfunction, cardiovascular disease , viral infection, inflammation, metabolic/endocrine disturbances, and nervous system abnormalities. |